November 17, 2023
1 min watch
Save
VIDEO: CDK9 inhibitor shows ‘modest’ efficacy in various sarcomas
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
A CDK9 inhibitor, known as KB-0742, showed preliminary evidence of clinical activity in patients with various sarcomas, according to a study presented at the Connective Tissue Oncology Society Annual Meeting.
“The efficacy to date remains modest at this time,” Sandra D’Angelo, MD, research director of the sarcoma medical oncology service at Memorial Sloan Kettering Cancer Center, told Healio in a video interview.
Reference:
- Van Tine BA, et al. Paper 26. Presented at: Connective Tissue Oncology Society Annual Meeting; Nov. 1-4, 2023; Dublin.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
D’Angelo reports consulting/advising for Aadi Bioscience, Adaptimmune, Amgen, EMD Serono, GI Innovations, GSK, Immune Design, Immunocore, Incyte, Merck, Nektar, Pfizer, Rain Therapeutics and Servier; research funding from Amgen, Bristol Myers Squibb, Deciphera, EMD Serono, Incyte, Merck and Nektar; receiving travel/accommodations expenses from Adaptimmune, EMD Serono and Nektar; and being on a data safety monitoring board/advisory board for Adaptimmune, GSK, Merck and Nektar.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.